Canine cognitive dysfunction syndrome (CDS) affects more than 28% of dogs aged 11–12 and over 68% of dogs aged 15–16 — yet it remains dramatically underdiagnosed in general practice. This course covers the DISHAA framework for clinical recognition, the neuropathology of canine CDS and its parallels to human Alzheimer's disease, all FDA-approved and evidence-based treatment options including selegiline, medium-chain triglyceride diets, and environmental enrichment, and the emerging integrative evidence base including SAMe, phosphatidylserine, and melatonin. We follow Biscotti, a 13-year-old Cavalier King Charles Spaniel whose owners think he's 'just getting old.' Earn 1.0 RACE CE credit.
Opening case: Biscotti, a 13-year-old Cavalier King Charles Spaniel presenting for 'just acting old.' His owners describe nighttime restlessness, occasional house soiling, and staring at the wall. A thorough workup begins.
The six DISHAA domains — Disorientation, Interactions (changed), Sleep-wake cycle disruption, House soiling, Activity changes, Anxiety — with clinical examples, prevalence data, and the validated screening questionnaire
Beta-amyloid plaques, tau protein, oxidative neuronal damage, and dopaminergic decline in canine CDS; parallels to human Alzheimer's disease; ruling out hypothyroidism, hypertension, brain tumors, hearing/vision loss, pain, and urinary disorders
10 questions · Passing score: 70%
Complete all course modules to unlock the assessment. Upon passing, your CE certificate will be generated automatically.
Selegiline (Anipryl) — MOA, dosing (0.5 mg/kg PO SID in the morning), expected timeline, drug interactions, and monitoring; Hill's b/d and Purina Neuro Care diets — MCT evidence, caprylic acid, and dietary antioxidants
SAMe evidence and dosing, phosphatidylserine mechanism and dosing, melatonin for sleep-wake disruption, omega-3s and brain health, acupuncture and neuroplasticity, the enrichment prescription, and caregiver burden reduction
Mild, moderate, and severe CDS staging; realistic prognosis conversations; the difference between 'managing decline' and 'giving up'; Biscotti's 12-month outcome